Center-Authored Papers

Filters: Author is Till, Brian G  [Clear All Filters]
2008
Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger WI, Press OW.  2008.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.. Leukemia & lymphoma. 49(6):1062-73. Abstract
Till BG, Martins RG.  2008.  Response to paclitaxel in adenoid cystic carcinoma of the salivary glands.. Head & neck. 30(6):810-4. Abstract
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW.  2008.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.. Journal of immunology (Baltimore, Md. : 1950). 180(10):7028-38. Abstract
Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ et al..  2008.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.. Blood. 112(6):2261-71. Abstract
2009
Till BG, Press OW.  2009.  Treatment of lymphoma with adoptively transferred T cells.. Expert opinion on biological therapy. 9(11):1407-25. Abstract
2010
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.  2010.  Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.. Journal of immunology (Baltimore, Md. : 1950). 184(8):4284-94. Abstract
2011
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
2012
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE et al..  2012.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.. Blood. 119(17):3940-50. Abstract
Till BG, Madtes DK.  2012.  BCNU-associated pneumonitis: portrait of a toxicity.. Leukemia & lymphoma. 53(6):1019-1020.
Till BG, Press OW.  2012.  Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.. Immunotherapy. 4(5):483-5. Abstract
2013
Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC et al..  2013.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.. PloS one. 8(12):e82742. Abstract
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract
2015
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM et al..  2015.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.. Hematological oncology. 33(4):187-191. Abstract
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI et al..  2015.  High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97. Abstract
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI et al..  2015.  Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6. Abstract
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur SD, Balkan ER, Lin Y et al..  2015.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.. Blood. 125(13):2111-9. Abstract
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD et al..  2015.  Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
2016
Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ et al..  2016.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.. Cancer immunology research. Abstract
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG.  2016.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.. Cancer letters. 380(2):413-423. Abstract
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA et al..  2016.  Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers.. Cancer research. Abstract
2017
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L et al..  2017.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.. Journal of the National Cancer Institute. 109(1) Abstract
O'Steen S, Green DJ, Gopal AK, Orozko JJ, Kenoyer AL, Lin Y, Wilber SD, Hamlin DK, Fisher DR, Hylarides MD et al..  2017.  Venetoclax Synergizes with Radiotherapy for Treatment of B cell Lymphomas.. Cancer research. 77(14):3885-3893. Abstract
2019
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS et al..  2019.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.. Blood. 133(15):1652-1663. Abstract